The suit has been filed in the U.S. District Court for the District of Columbia against Cephalon. According to the Commission, Cephalon, faced with threat to its Provigil monopoly, paid more than $200 million to generic drug companies to abandon their patent challenges and forgo entry into the market until April 2012. As Cephalon's CEO allegedly put it shortly after entering these settlements: "We were able to get six more years of patent protection. That's $4 billion in sales no one expected".
The FTC is clearly taking the issue very seriously, see also here.
-
.png)
EC, here . [NotebookLM's own DeepDive here , just for fun] In our Article 19 Report we discussed this and how it could eventually trans... -
In the US, here . I posed the question this morning and received an answer within 30 minutes. That was efficient, thank you!
-
Here. Comments are all ❤️❤️❤️ for her, nice to see! A class apart as antitrust enforcer.
-
Here.
-
Here .
-
E.Klein, here.
-
Here . [I watched it all, pretty weird - the journalist was amazing]
-
Here . We've been playing ourselves with the idea of a DMA Lab for more than a year...Competition! [We didn't hear about Panelis...
No comments:
Post a Comment